(NASDAQ: PRCT) Procept Biorobotics's forecast annual revenue growth rate of 21.37% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Procept Biorobotics's revenue in 2025 is $299,907,000.On average, 15 Wall Street analysts forecast PRCT's revenue for 2025 to be $18,608,128,923, with the lowest PRCT revenue forecast at $17,768,273,730, and the highest PRCT revenue forecast at $19,861,485,674. On average, 15 Wall Street analysts forecast PRCT's revenue for 2026 to be $24,070,260,998, with the lowest PRCT revenue forecast at $22,714,646,429, and the highest PRCT revenue forecast at $25,407,435,632.
In 2027, PRCT is forecast to generate $30,057,093,023 in revenue, with the lowest revenue forecast at $27,681,694,205 and the highest revenue forecast at $32,247,533,712.